Treatment of 'de novo' PD patients with lisuride and L-deprenyl combined: A long term study

E. Martignoni, C. Pacchetti, L. Godi, E. Rainer, R. Horowski, G. Nappi

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty early idiopathic Parkinson's disease (IPD) subjects were treated with dopamine agonist lisuride in combination with MAO-B inhibitor selegiline (L-deprenyl) and compared to a group of 31 IPD patients treated with lisuride alone. The 4 year follow-up revealed that the patients treated with lisuride plus selegiline required lower daily doses of lisuride, with both lower percentage of side-effects and loss of efficacy. Early use of combined therapy with lisuride and selegiline has a better therapeutic index than lisuride alone, possibly due to a synergistic effect between lisuride and selegiline on dopaminergic transmission. Another advantage besides reduced daily doses of lisuride can be the postponing of L-dopa therapy and related long term complications.

Original languageEnglish
Pages (from-to)53-57
Number of pages5
JournalNew Trends in Clinical Neuropharmacology
Volume6
Issue number1-4
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology

Fingerprint Dive into the research topics of 'Treatment of 'de novo' PD patients with lisuride and L-deprenyl combined: A long term study'. Together they form a unique fingerprint.

Cite this